Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ERAS-601

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Erasca, UT MD Anderson Cancer Center

Drug class:

PTPN11 inhibitor

Related drugs:

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2
BRAF mutation	Solid Tumor	BRAF mutation	Solid Tumor	ERAS-601 Sensitive: C4 – Case Studies ERAS-601 Sensitive : C4	ERAS-601 Sensitive: C4 – Case Studies ERAS-601 Sensitive : C4
NF1 mutation	Non Small Cell Lung Cancer	NF1 mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib + ERAS-601 Sensitive: D – Preclinical gilteritinib + ERAS-601 Sensitive : D	gilteritinib + ERAS-601 Sensitive: D – Preclinical gilteritinib + ERAS-601 Sensitive : D
KRAS mutation	Pancreatic Ductal Adenocarcinoma	KRAS mutation	Pancreatic Ductal Adenocarcinoma	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D